Escitalopram Oxalate

The goal of this clinical trial is to learn if offering a Family Accommodation Reduction (FAR) intervention to family members before OCD patients start CBT can improve CBT outcomes. The current study will offer 6 sessions of Family Accommodation Reduction (FAR) or OCD psychoeducation for the family member before the person with OCD receives 12 sessions of group CBT (GCBT). The main questions it aims to answer are: * Is the addition of FAR associated with superior outcomes at the end of standard GCBT and at 3 month follow up in comparison to our control group? * Is reduction in Family Accommodation a mechanism by which FAR is impacting the outcomes of GCBT? Researchers will compare CBT outcomes between people whose family member received the FAR intervention versus psychoeducation and see if any benefits last at a 3-month follow-up. Participating Family Members will: * receive 6 weeks of FAR or Psychoeducation * answer online questionnaires at several time points throughout the study about OCD symptom severity, quality of life, and level of functioning for the person with OCD. Participating Patients will: * complete 12 weeks of CBT for OCD * answer online questionnaires at several time points throughout the study about OCD symptom severity, quality of life, and level of functioning.

This study aims primarily to test target engagement of dupilumab by assessing changes in peripheral immune markers following interleukin-4 receptor alpha (IL-4Rα) blockade in adults with major depressive disorder (MDD). Secondary aims include evaluating safety, tolerability, feasibility, and open-label effects on depressive symptoms, blood-based immune markers, blood-brain barrier (BBB) function, and functional brain reward circuitry.

Ketamine is often used to treat depression where standard treatments have failed. Yet, even with ketamine, depression can persist and make it difficult to keep up with life. This study examines whether it is practical, safe and helpful to use a talk therapy (Acceptance and Commitment Therapy, ACT) in patients with difficult-to-treat depression receiving ketamine through the Ketamine Intervention Program at UBC Hospital. Researchers expect that combining ACT plus Ketamine ("K-ACT") will be feasible, safe, and will help patients functioning better in their daily lives, feeling that they are recovering, and having fewer symptoms of depression.

The purpose of this study is to assess the efficacy, safety and tolerability of ALKS 7290 following oral administration in adult participants with Major Depressive Disorder.

More efficacious treatments for Major Depressive Disorder (MDD) in Veterans are urgently needed. Psilocybin is a promising novel treatment that is likely to be the first FDA-approved psychedelic, but its safety and efficacy remain unclear. To address this gap, the investigators propose a randomized controlled trial of a single dose of psilocybin paired with a brief course of a VA-endorsed evidence-based psychotherapy (Acceptance and Commitment Therapy) in Veterans with MDD. Our trial addresses key limitations of previous studies including the challenge of management of expectancy effects, a focus on Veterans with input from Veterans, and a study population that reflects the demographics and medical and psychiatric complexity of the VHA patient population. Our study also explores psilocybin's antidepressant mechanisms focusing on changes in psychological flexibility and synaptic plasticity. In sum, this study will provide critical and timely data to determine if psilocybin treatment is a safe and efficacious treatment for MDD in Veterans.

This study utilizes mobile health methods, including smartphone technology, subjective self-reports measures of emotion, behavioral tasks, functional Magnetic Resonance Imaging (fMRI), physiological measures of attention and arousal, and measures of health and social support to identify neural mechanisms associated with individual differences in the temporal course of emotional responses. The aim of this project is to utilize real-world and personally relevant events as stimuli to better understand how the temporal course of emotional responses relate to risk for developing mental disorders.

Subclinical depression - depressive symptoms that fall below the threshold for major depressive disorder - is common in young adults and predicts later depressive episodes, yet it often goes untreated. This study tests whether a brief, remotely delivered non-deceptive (open-label) placebo intervention reduces subclinical depressive symptoms over approximately two weeks. Participants aged 18-30 living in Ohio, with PHQ-8 scores in the 5-9 range, are randomly assigned to one of three groups: a non-deceptive placebo group, a blinded control group, or an unblinded control group. All participants complete three remote sessions over 16-18 days and complete the same assessments on the same schedule. Participants in the non-deceptive placebo group additionally receive psychoeducation about placebo effects and placebo pills that are explicitly described as containing no active ingredients, which they take twice daily for two weeks. Participants in the unblinded control group are told they have been assigned to a control condition. Participants in the blinded control group are not told their group assignment until debriefing at the end of the study. The study has two aims. The first is to estimate the effect of the non-deceptive placebo intervention on depressive symptoms and related outcomes. The second is methodological: to determine whether telling control participants that they are in a control group changes their outcomes, and therefore whether the choice of control condition systematically biases estimates of non-deceptive placebo effects.

The goal of this study is to learn if a meditation intervention called Transcendental Meditation or TM can be used in a small department at Weill Cornell Medicine to help reduce employees' levels of burnout, anxiety, insomnia, and depression as well as to determine the feasibility and acceptability of the meditation practice by Weill Cornell employees. The main question the study aims to answer is whether: • Levels of burnout, anxiety, insomnia, and depression will be decreased, and overall mental well-being will improve over a 3.5-month period before and after TM intervention. Participants will attend 9 sessions total (8 group sessions and 1 individual session) with a certified TM instructor from The David Lynch Foundation Institute for Mental Health and Resilience where they will gain experience in proper TM techniques. Also, participants will conduct 2 of their own TM sessions at home daily during the course of this study.

The purpose of this research is to see if an experimental treatment for depression called intermittent theta burst stimulation (iTBS), a form of transcranial magnetic stimulation (TMS) can be improved for better results using electroencephalography (EEG) recordings (brain waves) for individuals with Major Depressive Disorder (MDD). This is a feasibility study to test a "closed-loop" procedure which guides the timing of this FDA-cleared form of TMS. Each participant will receive an active experimental treatment, and the timing of the TMS pulses will be at one of three phases in the brain wave of interest.

The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (MDD) who are already taking the anti-depressant medication Lexapro (escitalopram). The main questions it aims to answer are: 1. Does adalimumab improve the symptoms of some patients with MDD who are already taking an anti-depressant? 2. What characteristics predict for whom adalimumab has anti-depressant properties. Researchers will compare adalimumab to a placebo (a look-alike substance that contains no drug) to see if adalimumab works to improve depressive symptoms as an add-on drug to the anti-depressant Lexapro (escitalopram). For these primary aims the participants will: 1. Visit the clinic once every 2 weeks for a checkups and injection of adalimumab or placebo from the study psychiatrist (Day 1, 15, 29, and 43 for injections) 2. Complete short (\<5 min) daily surveys for the 57 day duration of the study.

This study will compare transcranial magnetic stimulation (TMS) with sham TMS in people with opioid use disorder who are taking buprenorphine and have major depressive disorder with ongoing depressive symptoms. The study will evaluate whether TMS improves depressive symptoms and reduces opioid craving. The study will also assess smoking behaviors, treatment acceptability, and any side effects related to TMS.

This study aims to evaluate the clinical efficacy and neurophysiological mechanisms of home-based spaced tDCS in TRD through a randomized, double-blind, sham-controlled trial conducted under remote supervision. Specifically, this trial will: (1) compare the efficacy of active versus sham spaced tDCS on depressive symptom severity in individuals with TRD and (2) characterize neurophysiological changes associated with spaced tDCS using TMS-EEG, TMS-EMG and resting state EEG.